NASDAQ : CERS

Cerus Corporation

$3.115 USD

-$0.09 (-2.96%)

Volume
1.16M
Average Volume
2.71M
Market Capitalization
$624.15M
P/E Ratio
-60.72
Dividend Yield
0.00%
Price Target
$4.00
Year High
$3.47
Year Low
$1.15
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$1.63
Source Headline
Cerus Corporation to Release Second Quarter 2026 Financial Results on July 30, 2026

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its second quarter 2026 financial results will be released on Thursday, July 30, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relati.

businesswire.com - 2026-07-16 16:01:00

Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today a company-sponsored lunch symposium and a selection of abstracts at the International Society of Blood Transfusion (ISBT) 39th International ISBT Congress, taking place in Kuala Lumpur, Malaysia, from June 20 through June 24, 2026. Transfusion medicine experts and professionals from around the world are expected to attend the ISBT Congress. “We look forward to highlighting how blood centers around the world are l.

businesswire.com - 2026-06-17 08:30:00

Cerus Corporation Closes New Debt Facility of Up to $110 Million

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the closing of a new debt facility with MidCap Financial (MidCap), providing up to $110 million. The facility consists of a 5-year term loan and an asset-backed revolving loan. The refinancing is expected to reduce annual cash interest expense by up to $3.5 million, reflecting lower borrowing costs and an approximately $30 million reduction in outstanding term loan balance. Initial proceeds from the loan, togethe.

businesswire.com - 2026-06-08 08:30:00

Bradley L. Radoff Announces Intent to Withhold Votes from Chair and CEO William Greenman and Director Ann Lucena

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff, a significant shareholder of Cerus Corporation (NASDAQ: CERS) (“Cerus” or the “Company”), today announced his intention to withhold support for the Company's two director nominees at the upcoming 2026 annual meeting in the below open letter to shareholders. *** May 27, 2026 Fellow Shareholders, I am an individual shareholder in Cerus managing my own capital. In light of the Company's negative returns and failure to achieve profitability over the past.

businesswire.com - 2026-05-27 11:35:00

Cerus Corporation: Strong Q1 Results Validate The Turnaround Thesis

Cerus' Q1 2026 product revenues grew another 24% YoY. This was mainly thanks to strong platelet demand and rapid IFC adoption. Management raised its 2026 product revenue guidance to $227-$231 million, which would imply promising 10%-12% YoY growth. IFC volumes rose about 120% YoY, making it the clearest current growth vertical beyond platelets.

seekingalpha.com - 2026-05-10 07:51:01

Cerus Corporation (CERS) Q1 2026 Earnings Call Transcript

Cerus Corporation (CERS) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-01 04:21:34

Cerus Corporation Announces First Quarter 2026 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the first quarter ended March 31, 2026, and provided a business update. “We delivered a strong start to 2026, with first quarter performance driven by strength across our business, in particular by increasing demand for our INTERCEPT Fibrinogen Complex,” said William “Obi” Greenman, Cerus' president and chief executive officer. “As a result, we are raising our product revenue guidance for th.

businesswire.com - 2026-04-30 16:01:00

Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the signing of a new, four-year supply agreement with Établissement Français du Sang (EFS), the French Blood Establishment, for the INTERCEPT Blood System. The agreement covers the INTERCEPT Blood System for platelets and plasma as well as the next generation, LED-based INT200 illumination device. “We are proud to announce a new four-year supply agreement with the French Blood Establishment,” said Christian Boute.

businesswire.com - 2026-04-27 08:00:00

Critical Analysis: Akanda (NASDAQ:AKAN) and Cerus (NASDAQ:CERS)

Cerus (NASDAQ: CERS - Get Free Report) and Akanda (NASDAQ: AKAN - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends. Profitability This table compares Cerus and Akanda's net margins,

defenseworld.net - 2026-04-17 01:29:11

Get CERS Insider Trade Alerts

CERS Price Target Summary

Last Month

$0.00

0 analysts

Last Quarter

$4.00

1 analysts

Last Year

$4.00

1 analysts

All Time

$4.00

4 analysts

CERS Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2026-05-01 BTIG Upgrade Neutral Buy
2025-02-21 Cantor Fitzgerald Maintain Overweight Overweight
2024-10-17 Stifel Maintain Buy Buy
2024-05-03 Cantor Fitzgerald Maintain Overweight Overweight
2024-03-07 Stephens & Co. Maintain Equal Weight Equal Weight
2024-03-06 Cantor Fitzgerald Maintain Overweight Overweight
2023-01-20 BTIG Downgrade Buy Neutral
2020-05-27 Stifel Maintain Buy Buy
2020-04-16 Stephens & Co. Maintain Overweight Overweight
2020-02-26 BTIG Research Maintain Buy Buy
2020-02-26 BTIG Maintain Buy Buy
2019-11-13 BTIG Upgrade Neutral Buy
2019-11-13 BTIG Research Upgrade Neutral Buy
2019-08-28 Stifel Maintain Buy Buy
2016-04-22 BTIG Maintain Buy Buy
2016-04-22 BTIG Research Maintain Buy Buy
2015-12-17 Wedbush Downgrade Outperform Neutral
2015-04-24 BTIG Research Maintain Buy Buy
2015-02-27 Cantor Fitzgerald Maintain Buy Buy
2014-12-02 MLV & Co. Maintain Buy Buy
2014-05-05 Cantor Fitzgerald Maintain Buy Buy
2013-09-30 Wedbush Maintain Outperform Outperform
2013-03-01 McNicoll Lewis Vlak Maintain Buy Buy
2013-02-07 Canaccord Genuity Maintain Buy Buy
2012-10-08 Cowen & Co. Maintain Outperform Outperform
2012-04-17 Cantor Fitzgerald Maintain Buy Buy